Company news

ClearPoint Neuro Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

April 22, 2024

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

April 15, 2024

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

March 18, 2024

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

March 11, 2024

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System

March 10, 2024

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

February 29, 2024

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

February 28, 2024

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

February 27, 2024

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

February 20, 2024

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

January 23, 2024

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

January 21, 2024

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

January 15, 2024

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

January 7, 2024

ClearPoint Neuro Reports Third Quarter 2023 Results

November 8, 2023

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

October 25, 2023

ClearPoint Neuro Reports Second Quarter 2023 Results

August 7, 2023

ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

July 24, 2023

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

May 23, 2023

ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference

May 17, 2023

ClearPoint Neuro Reports First Quarter 2023 Results

May 10, 2023

ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles

May 9, 2023

ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

April 27, 2023

ClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023: ClearPoint Maestro® Brain Model and ClearPoint Prism™ Neuro Laser Therapy System

April 19, 2023

ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model

April 17, 2023

ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil

April 12, 2023

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

April 10, 2023

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

March 27, 2023

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results

February 28, 2023

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023

February 14, 2023

ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue

January 10, 2023

ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Sweden

December 11, 2022

ClearPoint Neuro to Present at Upcoming Investor Conferences

November 8, 2022

ClearPoint Neuro Reports Third Quarter 2022 Results

November 7, 2022

ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022

October 25, 2022

ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

September 21, 2022

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

September 19, 2022

ClearPoint Neuro Announces FDA Clearance for Software Version 2.1

September 18, 2022

ClearPoint Neuro Reports Second Quarter 2022 Results

August 8, 2022

ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model

August 8, 2022

ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

August 7, 2022

ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022

July 25, 2022

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency

July 20, 2022

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

June 28, 2022

ClearPoint Neuro Announces Receipt of MDSAP Certification

June 1, 2022

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency

May 19, 2022

ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC

May 12, 2022

ClearPoint Neuro Reports First Quarter 2022 Results

May 10, 2022

ClearPoint Neuro and Higgs Boson Health Announce Collaboration

May 2, 2022

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1

April 27, 2022

ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room

April 26, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 61 decks. Every deck is listed under its year.